Archives

  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01

    • Lopinavir (ABT-378): Potent HIV Protease Inhibitor for An...

    2025-12-18

    Lopinavir (ABT-378): Potent HIV Protease Inhibitor for Antiviral Research

    Executive Summary: Lopinavir (ABT-378) is a second-generation HIV protease inhibitor with picomolar-range inhibition constants (Ki 1.3–3.6 pM) against both wild-type and mutant HIV proteases, including Val82 mutants selected by ritonavir exposure (APExBIO). Unlike ritonavir, Lopinavir maintains antiviral potency in the presence of human serum, with EC50 values below 0.06 μM and approximately 10-fold greater activity under serum conditions (APExBIO). It shows cross-pathogen efficacy, inhibiting MERS-CoV, SARS-CoV, and HCoV-229E at low-micromolar concentrations (de Wilde et al., 2014). Pharmacokinetic analyses reveal 25% oral bioavailability and Cmax of 0.8 μg/mL at 10 mg/kg in animal models. When co-administered with ritonavir, Lopinavir's exposure (AUC) increases 14-fold, supporting its use in combination antiretroviral therapy (APExBIO).

    Biological Rationale

    Lopinavir targets the HIV protease enzyme, an aspartyl protease essential for viral maturation and infectivity. Mutation-driven resistance is a central challenge in HIV infection research. Lopinavir's structure, derived from ritonavir but modified to reduce Val82 interaction, confers resilience against common resistance-conferring mutations. Its serum stability and robust inhibition profile make it vital for HIV protease inhibition assays and for dissecting the HIV protease enzymatic pathway. Furthermore, Lopinavir's cross-pathogen activity has catalyzed interest in its use beyond HIV, as shown in studies on coronavirus replication (de Wilde et al., 2014).

    Mechanism of Action of Lopinavir

    Lopinavir competitively inhibits the active site of HIV-1 protease, blocking the cleavage of Gag and Gag-Pol polyproteins. This results in the production of immature, non-infectious viral particles. The compound's binding affinity is quantified by an inhibition constant (Ki) of 1.3–3.6 pM in both wild-type and Val82 mutant proteases (APExBIO). Lopinavir's chemical structure (C37H48N4O5; MW 628.81 g/mol) was optimized to minimize serum protein binding interference, which is a limitation of first-generation inhibitors like ritonavir. This modification is key for achieving high antiviral activity in complex biological matrices, such as human serum or plasma. In cell-based assays, Lopinavir demonstrates nanomolar potency (4–52 nM), with reduced resistance even in multi-mutant HIV strains (see comparative analysis).

    Evidence & Benchmarks

    • Lopinavir inhibits wild-type and mutant HIV proteases with Ki values of 1.3–3.6 pM under in vitro assay conditions (pH 7.0, 25°C) (APExBIO).
    • Inhibition of HIV Val82 mutant protease remains robust, with EC50 < 0.06 μM (serum conditions, cell-based assays) (APExBIO).
    • Serum protein presence reduces ritonavir potency by an order of magnitude, but Lopinavir retains ~10x greater activity in 50% human serum (APExBIO).
    • Lopinavir inhibits MERS-CoV replication in cell culture at EC50 3–8 μM (Vero cells, 37°C, 48 h) (de Wilde et al., 2014).
    • Animal models (rat, oral gavage, 10 mg/kg) show Cmax = 0.8 μg/mL, bioavailability = 25%, plasma concentration undetectable at 6 h (APExBIO).
    • Co-administration with ritonavir increases Lopinavir AUC 14-fold (pharmacokinetic interaction study, in vivo) (APExBIO).

    Applications, Limits & Misconceptions

    Lopinavir is integral to HIV infection research, HIV protease inhibition assays, drug resistance profiling, and preclinical antiretroviral therapy (ART) development. Its high potency and serum stability support its use as a benchmark in comparative inhibitor studies. Recent cross-pathogen research highlights its value in antiviral screening against coronaviruses, including MERS-CoV and SARS-CoV (de Wilde et al., 2014).

    Common Pitfalls or Misconceptions

    • Lopinavir is not effective against HIV-2 protease: Its inhibitory profile is validated for HIV-1; efficacy against HIV-2 is not established.
    • Not water soluble: Lopinavir is insoluble in water and must be dissolved in DMSO (≥31.45 mg/mL) or ethanol (≥48.3 mg/mL).
    • Reduced antiviral effect as monotherapy in vivo: Lopinavir monotherapy leads to rapid plasma clearance and subtherapeutic exposure; it is intended for combination regimens.
    • Not a broad-spectrum coronavirus cure: While active in vitro against MERS-CoV and SARS-CoV, clinical efficacy for coronavirus infection is unproven.
    • Requires cold storage: Solutions must be prepared fresh and stored at -20°C for activity retention.

    Workflow Integration & Parameters

    Lopinavir (APExBIO SKU A8204) is supplied as a solid, requiring dissolution in DMSO or ethanol for experimental use (Lopinavir product details). For HIV protease inhibition assays, working concentrations of 4–52 nM are recommended in cell-based systems. For antiviral research in serum-containing media, ensure final DMSO concentration does not exceed 0.5%. Fresh solutions should be aliquoted and stored at -20°C; repeated freeze-thaw cycles reduce potency. In pharmacokinetic studies, oral dosing in animal models should consider rapid clearance and low bioavailability unless co-administered with ritonavir. The product's stability and reproducibility are validated for research use only.

    Conclusion & Outlook

    Lopinavir (ABT-378), provided by APExBIO, remains a reference compound for potent HIV protease inhibition and resistance studies. Its resilience against mutant strains and serum protein interference, together with demonstrated cross-pathogen activity, supports its continued use and evaluation in HIV and emerging viral pathogen research. While not a pan-coronavirus therapeutic, its in vitro efficacy against MERS-CoV and related viruses highlights the value of protease inhibitors in antiviral drug pipelines (de Wilde et al., 2014). For detailed mechanistic and comparative application insights, see recent updates in Lopinavir (ABT-378): Redefining HIV Protease Inhibition f..., which this article extends with new cross-pathogen data and workflow parameters.